Dr. Carl Ade
The Clinical Integrative Physiology Laboratory works on directed identification and characterization of patients at risk of developing cancer treatment-related cardiotoxicity, in order to mitigate cardiovascular dysfunction while optimizing cancer outcomes. This work is critical given that the 14 million pediatric and adult cancer survivors in the U.S. who demonstrate continued improvements in anti-cancer treatment efficacy have also experienced a parallel rise in the incidence of cancer treatment-related toxicity, leading to morbidity and mortality.
Cancer treatment-related cardiotoxicity can occur as a consequence of direct and indirect effects on cardiac myocytes, the vascular endothelium and vascular smooth muscle, all of which adversely impact cardiovascular health. We investigate changes in cardiovascular function resulting from chemotherapy, immunotherapy, hormone deprivation and radiation, with the goal of developing screening, diagnostic and/or management strategies that can be integrated with evidence-based cancer treatment regimens. We aim to determine the biological mechanisms that mediate cancer treatment-related cardiotoxicity as well as develop and evaluate the efficacy of interventions—both lifestyle and pharmacologic—for mitigating or reversing these adverse changes in physiological function.